Rosen Law Firm probes potential securities class action over Immutep disclosures

  • Rosen Law Firm said it is investigating potential securities claims on behalf of Immutep shareholders over allegations of materially misleading business information.
  • The investigation follows Immutep’s announcement that an independent data monitoring committee recommended discontinuing the TACTI-004 Phase III trial of eftilagimod alfa in first-line non-small cell lung cancer after an interim futility analysis.
  • After the announcement, Immutep’s ADR fell $2.28 to $0.48, a decline of 82.6%.
  • The firm said it is preparing a securities class action seeking recovery of investor losses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603191507PRIMZONEFULLFEED9675459) on March 19, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.